The first exercise period for Modus Therapeutics' warrants of series TO 2030 commences on 14 September 2026
On 26 June 2025, the board of directors of Modus Therapeutics Holding AB (publ) resolved to carry out a rights issue of units, which was approved by the general meeting on 29 July 2025, through which warrants of series TO 2030 (the “Warrants”) were issued. The first exercise period for the Warrants commences on 14 September 2026 and runs until 27 September 2026.
Warrants of series TO 2030 in brief
• The first exercise period: 14 September 2026 – 27 September 2026.
• Subscription price: SEK 0.40 per new share.
• Issue volume: There are 38,084,264 outstanding warrants of series TO 2030. Upon full exercise of all warrants, 38,084,264 new shares will be issued in Modus Therapeutics and the Company will receive approximately SEK 15.2 million before issue costs.
Upon full exercise of the warrants of series TO 2030, the number of shares and votes in Modus Therapeutics will increase by 38,084,264.
Subsequent exercise periods
In addition to the first exercise period, the Warrants may be exercised during the following periods:
• 13 September 2027 – 26 September 2027
• 18 September 2028 – 30 September 2028
• 18 September 2029 – 29 September 2029
• 16 September 2030 – 28 September 2030
Key dates for the first exercise period
14 September 2026 – The first exercise period commences
27 September 2026 – The first exercise period ends
29 September 2026 – Planned date for publication of the outcome of the exercise
12 October 2026 – Planned date for conversion of interim shares into shares
Subscription forms are available on Bergs Securities’ website, www.bergssecurities.se. Complete terms and conditions for the warrants of series TO 2030 are available on Modus Therapeutics’ website.
How to exercise your warrants of series TO 2030
Your warrants may be registered in one of two ways:
1. In a securities account at a bank or with another custodian (for example Avanza or Nordnet), in an investment savings account (ISK), or in an endowment insurance policy (KF). In this case, your warrants are nominee-registered.
2. In a CSD account (a CSD account begins with three zeros). In this case, your warrants are directly registered.
If Your Warrants Are Nominee-Registered
Subscription and payment for new shares, through the exercise of warrants, shall be made to the respective bank or other custodian where the warrants are registered. Subscription and payment shall be made in accordance with the instructions provided by each such bank or custodian. Banks/custodians usually send a digital notification to the account holder; otherwise, it is usually sufficient to log in to the securities account from the first day of the exercise period in order to receive instructions on how to exercise warrants to subscribe for new shares. Please contact your bank or custodian if you cannot find these instructions. Note that banks and other custodians may set different deadlines for subscription; it is therefore recommended to contact your bank/custodian early during the exercise period for information on subscription and payment. Subscribed and paid shares may be registered in your securities account as "interim shares" or "IA" until the registration of the new shares is completed at the Swedish Companies Registration Office (Bolagsverket), at which point interim shares will automatically be converted to shares in Modus Therapeutics.
If Your Warrants Are Directly Registered
Subscription for new shares, through the exercise of warrants, shall be made by submitting a fully completed subscription form to Bergs Securities. Payment shall be made in connection with the submission of the subscription form to Bergs Securities, in accordance with the payment instructions on the subscription form. The completed subscription form and payment must be received by Bergs Securities no later than 27 September 2026. Subscribed and paid shares will be registered in your CSD account as "interim shares" ("IA") until the registration of the new shares is completed at the Swedish Companies Registration Office (Bolagsverket), at which point interim shares will automatically be converted to shares in Modus Therapeutics.
Unexercised warrants may be exercised during subsequent exercise periods.
This information was submitted for publication, through the agency of the contact persons below, on 11 September 2026 at 07:30 CEST.
For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com
Certified Adviser
Bergs Securities AB
Hemsida: www.bergssecurities.se
About Modus Therapeutics and sevuparin
Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.